MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancerPaul Vilquin, Pascale A. Cohen|Breast Cancer Research|2015Cited by 79
Phase I–II Open-Label Multicenter Study of Palbociclib + Vemurafenib in <i>BRAF</i> V600MUT Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response MechanismBaptiste Louveau, Célèste Lebbé, Thierry Lesimple et al.|Clinical Cancer Research|2021Cited by 19